ClinicalTrials.gg
RecruitingNCT07035925Updated Mar 31, 2026

Study Evaluating the Safety and Efficacy of an ECM Hydrogel for the Treatment of Anorectal Fistulas

An interventional study of ECMT-100 in Fistula in Ano, sponsored by ECM Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by ECM Therapeutics, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.

Planned enrollment
12th of 15
10 · median 21
Started
2025
with 2 others
No phase
8 of 20
3 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
ECM Therapeutics, Inc.

Among the 20 studies in Rectal Fistula with a site in United States, this one is the 12th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 with no phase, and was the 17th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rectal Fistula with a site in United States, or all of them as a file.
02

Study summary

Safety and Efficacy of ECMT-100 for the Treatment of Anorectal Fistulas

Read the detailed description

ECMT-100 is a colloidal hydrogel derived from extracellular matrix (ECM), formulated to adhere to sub-epithelial soft tissue and allow for filling of anorectal fistulas to reinforce and promote fistula tract closure. ECMT-100 is a medical device and should be administered via catheter within the fistula tract following curettage of the tract, with draining setons used preoperatively.

ECMT-100 is a mucoadhesive hydrogel composed of ECM formulated to adhere to the gastrointestinal mucosa, fill the transsphincteric fistula tract, and promote tract closure by allowing for timely host tissue integration without fecal incontinence.

03

Conditions studied

  • Fistula in Ano

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects at least 18 years of age.
  • Provide
  • Non-pregnant females
  • Clinical diagnosis of 1 high transsphincteric anorectal fistula, with 1 internal opening and 1-2 external openings, with a single seton in place.
  • Seton placement for a minimum of four (4) weeks
  • Willingness to participate in post-operative follow-up evaluations.

Exclusion criteria

Exclusion Criteria:

  • Inability to provide .
  • Medical history of Crohn's disease/Ulcerative Colitis.
  • Subjects with multiple fistula tracts (defined as >1 internal opening and/or >2 external openings), secondary tracts, horseshoe fistulas, J-pouch fistulas, superficial fistulas, ano/recto-vaginal fistulas or rectourethral fistulas.
  • Previous fistulotomy/fistulectomy at the target treatment site (a history of these procedures at other locations is not exclusionary).
  • Fistula of traumatic origin including obstetric.
  • Evidence of ongoing local infection.
  • Evidence of active abscess at the time of treatment.
  • Chronic disease such as congestive heart failure, liver disease, renal disease, insulin dependent diabetes (as determined by reading from past 6-12 months), or any chronic illness that may interfere with participation in this study.
  • Active and unstable disease state or infection anywhere in the body per Investigator's evaluation and determination.
  • disease that is not stable.
  • Subjects who are such as known (HIV) or currently receiving chemotherapy or radiation therapy.
  • Ongoing use of antiplatelet drugs. Subjects may be included in the study if antiplatelet drugs have been stopped for 5 to 7 days prior to surgery.
  • Known coagulopathy (demonstrated by stated or medical record history of diagnosis)
  • Pregnancy
  • Previous history of radiation therapy in the area of the fistula.
  • History of collagen disease.
  • Known allergy to porcine products.
  • Religious objection to use of porcine products.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment

    ECMT-100 Subjects will be followed for 12 months following last treatment with ECMT-100. Subjects are eligible for one repeat treatment as determined by the clinician/investigator at or prior to the 6-month visit.

    Device: ECMT-100

Interventions

  • DeviceECMT-100

    Colloidal hydrogel

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of Adverse Events

    Time frame: 12 months from treatment

Secondary outcomes

  1. Percentage of Subjects in whom external openings of the fistula have closed

    Physical exam to confirm closure and absence of discharge

    Time frame: 12 months from treatment

  2. Changes in Fecal Incontinence

    Wexner Score - Cleveland Clinic Fecal Incontinence Score; changes from baseline

    Time frame: 12 months from treatment

  3. Changes in Quality of Life

    Medical Outcomes Study Questionnaire Short Form 36; changes from baseline

    Time frame: 12 months from treatment

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.

Of 58 interventional studies with no phase under Rectal Fistula, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
Jun 25, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Feb 24, 2027
CompletionEst.
Apr 24, 2028
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07035925
Lead sponsor
ECM Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Nov 24, 2025
Primary completion
Feb 24, 2027 (estimated)
Completion
Apr 24, 2028 (estimated)
Last update
Mar 31, 2026

Study contacts

Julie Cramer
Contact
julie@clinicalresearchstrategies.com
330-507-0801
Cynthia Berringer
Contact
cberringer@ecmtherapeutics.com
412-638-9986

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion